Plant Name: Phlomoides rotata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NMUR2; | |
| ADRA2C; ADRA2A; | |
| TDP1; RECQL; PKM; GLO1; HSD17B1; AKR1B1; HSD17B10; ALOX15; ALDH1A1; ALOX12; AKR1B10; NOX4; USP2; TNKS; PARP1; TNKS2; POLB; CD38; | |
| PTPN1; | |
| ACHE; GAA; | |
| CFTR; | |
| CDK8; CSNK2A1; SYK; FLT3; GSK3B; MAPK1; PRKCA; CDK9; CDK6; | |
| CA7; CA5A; CA3; CA14; CA5B; CA1; CA12; CA9; CA4; CA6; CA2; | |
| PPARA; PPARD; | |
| AR; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS2; XDH; | |
| MMP12; MMP2; MMP9; MMP1; | |
| TLR2; | |
| HIF1A; NFKB1; TP53; | |
| ABCC1; ABCG2; | |
| LMNA; FABP5; FABP2; FABP4; MAPT; FABP3; THPO; RAB9A; NPC1; APP; TTR; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| Protein Kinase | CDK9 | Cyclin-dependent kinase 9 | P50750 | CHEMBL3116 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.293E-11 | 1.611E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.451E-10 | 7.707E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.084E-10 | 1.744E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.714E-09 | 1.299E-06 | ABCC1, ALOX12, ALOX15, ALOX5, SYK, TLR2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.718E-09 | 1.519E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.154E-09 | 1.615E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4, PTGS2 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.564E-08 | 5.473E-06 | ADRA2A, CA2, CA7, CD38, CDK6, CFTR, HIF1A, MAPK1, NPC1, PARP1, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.022E-08 | 6.327E-06 | ABCG2, ACHE, ADRA2A, ADRA2C, APP, CD38, CSNK2A1, ESR1, ESR2, FLT3, L3MBTL1, MAPK1, MAPT, MMP9, NFKB1, PARP1, PKM, PTGS2, RAB9A, SMN1, SMN2, TP53, TTR, USP2, XDH |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.172E-08 | 6.578E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.208E-08 | 1.022E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 7.178E-08 | 1.303E-05 | CA2, CA7, CFTR, HIF1A, MAPK1, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.849E-07 | 3.073E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.519E-07 | 5.396E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 6.704E-07 | 9.541E-05 | ALOX12, ALOX15, ALOX5, PTGS2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 2.470E-06 | 3.039E-04 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 4.517E-06 | 5.162E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 5.325E-06 | 5.947E-04 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 6.509E-06 | 7.074E-04 | AR, CA2, CD38, FLT3, NPC1, PARP1, PTGS2, TLR2 |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 6.529E-06 | 7.074E-04 | APP, CDK6, CDK9, GSK3B, HIF1A, MAPK1, MAPT, PARP1, PTGS2, PTPN1, SYK, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 7.865E-06 | 8.194E-04 | AR, CDK8, CDK9, ESR1, ESR2, PPARA, PPARD |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 1.035E-05 | 1.034E-03 | CA2, CA7, CFTR |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.419E-05 | 1.323E-03 | AR, CYP19A1, ESR1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.885E-05 | 1.704E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.005E-05 | 1.747E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.005E-05 | 1.747E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.005E-05 | 1.747E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 2.451E-05 | 2.061E-03 | APP, CFTR, CYP19A1, CYP1B1, NPC1, PPARD |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 2.521E-05 | 2.103E-03 | MMP2, MMP9, PPARD, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 2.690E-05 | 2.236E-03 | CSNK2A1, GSK3B, MAPK1, PRKCA, TNKS |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 2.952E-05 | 2.416E-03 | ADRA2A, ALOX12, APP, HIF1A, MAPK1, MMP9, NOX4, PRKCA, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 4.027E-05 | 3.132E-03 | AKR1B1, CDK6, CFTR, CYP1B1, MAPK1, NFKB1, PTGS2, TP53 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 4.315E-05 | 3.296E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 4.542E-05 | 3.452E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| MF | GO:0003824; catalytic activity | GO:0008353; RNA polymerase II carboxy-terminal domain kinase activity | 4.737E-05 | 3.569E-03 | CDK8, CDK9, MAPK1 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 5.369E-05 | 3.976E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 5.674E-05 | 4.174E-03 | AKR1B1, AKR1B10, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AR, CA1, CA2, CA3, CA7, CDK6, CFTR, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HIF1A, HSD17B1, LMNA, MAPK1, MAPT, NFKB1, PKM, PRKCA, PTPN1, RAB9A, SMN1, SMN2, SYK, TNKS, TNKS2, TP53, XDH |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 5.733E-05 | 4.204E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 5.999E-05 | 4.255E-03 | APP, TLR2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.999E-05 | 4.255E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 5.999E-05 | 4.255E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 5.999E-05 | 4.255E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 5.999E-05 | 4.255E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 5.999E-05 | 4.255E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 5.999E-05 | 4.255E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0043168; anion binding | 6.698E-05 | 4.675E-03 | ABCC1, ABCG2, ALOX15, APP, CDK6, CDK8, CDK9, CFTR, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GSK3B, HSD17B1, MAPK1, NMUR2, NOX4, PKM, PPARD, PRKCA, RAB9A, RECQL, SYK, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0090330; regulation of platelet aggregation | 6.858E-05 | 4.756E-03 | ALOX12, PRKCA, SYK |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 7.027E-05 | 4.842E-03 | ALOX15, ESR1, GSK3B, MAPT, MMP1, PARP1, TP53 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 7.255E-05 | 4.969E-03 | APP, AR, CDK6, CYP1B1, FABP3, LMNA, NOX4, PPARD, PTGS2, TLR2, TP53, XDH |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 8.065E-05 | 5.437E-03 | APP, MAPK1, PARP1, PTGS2, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 8.202E-05 | 5.513E-03 | AKR1B1, CA3, CYP1A1, CYP1B1, MAPK1, NFKB1, POLB, TLR2, TP53 |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 9.519E-05 | 6.319E-03 | CDK9, ESR1, PPARA |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 9.783E-05 | 6.436E-03 | MAPK1, MAPT, PPARA, PTPN1, SYK, TP53 |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 9.896E-05 | 6.471E-03 | ABCC1, ABCG2, ACHE, ADRA2A, ADRA2C, ALOX12, ALOX15, APP, AR, CA12, CA14, CA2, CA4, CA9, CD38, CFTR, CSNK2A1, ESR1, FABP5, FLT3, GAA, GLO1, GSK3B, HSD17B10, L3MBTL1, MAPK1, MAPT, MMP2, NMUR2, PRKCA, PTPN1, RAB9A, SYK, TDP1, TLR2, TSHR |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.022E-04 | 6.665E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.069E-04 | 6.950E-03 | HIF1A, LMNA, PPARD, PTGS2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.107E-04 | 7.152E-03 | CYP1A1, POLB, TP53 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.170E-04 | 7.421E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.196E-04 | 7.421E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.196E-04 | 7.421E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.196E-04 | 7.421E-03 | TNKS, TNKS2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 1.196E-04 | 7.421E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.196E-04 | 7.421E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.196E-04 | 7.421E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.196E-04 | 7.421E-03 | ALDH1A1, AR |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.278E-04 | 7.861E-03 | AKR1B1, CYP1B1, MAPK1, MMP9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.278E-04 | 7.861E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 1.289E-04 | 7.902E-03 | ACHE, ADRA2A, CSNK2A1, FLT3, L3MBTL1, MAPT, MMP12, MMP9, PKM, PPARA, PTPN1, SYK, TLR2, TSHR |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.464E-04 | 8.760E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0000166; nucleotide binding | 1.614E-04 | 9.551E-03 | ABCC1, ABCG2, ALDH1A1, CDK6, CDK8, CDK9, CFTR, CSNK2A1, FLT3, GSK3B, HSD17B1, MAPK1, NMUR2, NOX4, PARP1, PKM, PRKCA, RAB9A, RECQL, SYK, TP53, XDH |
| BP | GO:0040007; growth | GO:0040008; regulation of growth | 1.668E-04 | 9.662E-03 | ALOX12, APP, AR, CD38, CSNK2A1, ESR2, HIF1A, MAPT, PPARD, TNKS2, TP53 |
| BP | GO:0008152; metabolic process | GO:1902652; secondary alcohol metabolic process | 1.717E-04 | 9.863E-03 | APP, CFTR, CYP3A4, NPC1, PPARD |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.080E-23 | 7.838E-20 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.941E-19 | 3.234E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.654E-16 | 1.448E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.027E-15 | 1.824E-12 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, GLO1, L3MBTL1, MMP1, MMP12, MMP2, MMP9, PARP1, PPARA, PPARD, PRKCA, PTPN1, TNKS, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.633E-23 | 1.247E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.621E-11 | 5.284E-09 | CYP2C9; APP; MAOA; ALOX5; ALOX15; MAPK1; PRKCA; ALOX12; CYP2C19; PTGS2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.705E-09 | 1.068E-07 | GSK3B; FLT3; MMP1; MMP2; PRKCA; PTGS2; HIF1A; MMP9; NFKB1; AR; CDK6; MAPK1; TP53; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 7.753E-08 | 2.429E-06 | HSD17B1; ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.999E-08 | 9.397E-07 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARA; PPARD |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.621E-07 | 5.409E-06 | MAOA; GAA; ALOX15; AKR1B1; ALOX12; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; CYP2C9; PKM; AKR1B10; HSD17B1; ALOX5; CYP1A2; ALDH1A1; CYP1A1; CD38; XDH |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.732E-08 | 2.429E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.877E-07 | 5.409E-06 | CYP2C9; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.921E-07 | 4.514E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.887E-06 | 4.174E-05 | MMP2; MAPK1; PRKCA; TP53; HIF1A; ESR1; MMP9; TLR2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.517E-07 | 4.073E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 2.139E-06 | 3.351E-05 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; NFKB1; TLR2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.431E-06 | 4.607E-05 | CDK6; MAPK1; PRKCA; TP53; MMP9; NFKB1; TLR2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 9.186E-07 | 1.570E-05 | MMP1; MMP2; MAPK1; MMP9; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.791E-06 | 7.258E-05 | ABCC1; CDK6; CYP1B1; MAPK1; PRKCA; PTGS2; TP53; MMP9; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.270E-05 | 1.256E-04 | GSK3B; MAPK1; PRKCA; TP53; ESR1; HIF1A |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.083E-05 | 1.198E-04 | PKM; FLT3; MAPK1; TP53; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.328E-06 | 1.096E-04 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.543E-05 | 1.450E-04 | GSK3B; MAPK1; ESR1; NFKB1; ESR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.134E-05 | 2.561E-04 | POLB; CDK6; PKM; SYK; MAPK1; TP53; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.252E-05 | 1.256E-04 | CYP2C9; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.319E-05 | 3.383E-04 | GSK3B; AR; MAPK1; TP53; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.651E-05 | 1.478E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.193E-04 | 7.731E-04 | GSK3B; CDK6; SYK; MAPK1; PRKCA; TP53; NFKB1; TLR2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 7.193E-05 | 5.201E-04 | MMP2; MAPK1; ESR1; MMP9; ESR2 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 5.335E-05 | 4.012E-04 | SYK; CSNK2A1; PARP1; PTGS2; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.523E-04 | 1.394E-03 | GSK3B; SYK; CSNK2A1; CD38; TP53; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.032E-04 | 7.188E-04 | CDK6; MAPK1; PRKCA; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.785E-04 | 1.090E-03 | ABCC1; MAPK1; PRKCA; TP53; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.107E-04 | 7.430E-04 | FLT3; MAPK1; NFKB1; PPARD |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.708E-05 | 2.314E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.847E-04 | 1.090E-03 | CDK6; MAPK1; PRKCA; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.880E-04 | 1.394E-03 | GSK3B; MAPK1; PPARA; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.648E-04 | 1.673E-03 | PARP1; LMNA; MAPK1; TP53; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.960E-04 | 1.116E-03 | CDK6; MAPK1; TP53; NFKB1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.894E-04 | 1.743E-03 | GSK3B; CSNK2A1; PRKCA; TP53; PPARD |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.892E-04 | 1.394E-03 | CDK6; MAPK1; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.892E-04 | 1.394E-03 | GSK3B; SYK; MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.892E-04 | 1.394E-03 | MAPK1; PTGS2; NFKB1; TLR2 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 8.356E-04 | 3.491E-03 | APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 9.891E-04 | 3.957E-03 | MMP2; MAPK1; PRKCA; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.599E-04 | 1.394E-03 | CA2; CYP3A4; CFTR; ABCG2 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 5.405E-04 | 2.363E-03 | CDK6; PTGS2; TP53; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.137E-03 | 4.364E-03 | CDK9; FLT3; TP53; MMP9; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.064E-03 | 4.168E-03 | MAPK1; PRKCA; HIF1A; NFKB1 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 8.182E-04 | 3.491E-03 | CA2; CD38; PRKCA; CFTR |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.358E-03 | 5.005E-03 | MAPK1; PTGS2; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.313E-03 | 4.936E-03 | PTPN1; GSK3B; PPARA; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.771E-03 | 6.166E-03 | MAPK1; PPARA; CFTR; NFKB1; TSHR |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.758E-03 | 6.166E-03 | ALOX5; MAPK1; NFKB1; TLR2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.870E-03 | 6.276E-03 | GSK3B; MAPK1; TP53; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.122E-03 | 1.459E-02 | MAPK1; PRKCA; MAPT; TP53; NFKB1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 5.022E-03 | 1.452E-02 | CD38; MAPK1; PRKCA; PTGS2 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 7.176E-03 | 1.927E-02 | GSK3B; MAPK1; PRKCA; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 7.610E-03 | 1.987E-02 | SYK; MAPK1; NFKB1; TLR2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 8.690E-03 | 2.178E-02 | CSNK2A1; TP53; NFKB1; TLR2 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 3.249E-03 | 1.018E-02 | SYK; MAPK1; PRKCA |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 6.478E-03 | 1.818E-02 | GSK3B; MAPK1; PRKCA |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.671E-03 | 1.131E-02 | CDK6; MAPK1; TP53 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 7.333E-03 | 1.942E-02 | MMP2; MAPK1; PRKCA |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 4.125E-03 | 1.231E-02 | CA2; PRKCA; CFTR |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 6.686E-03 | 1.848E-02 | THPO; FLT3; CD38 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 7.784E-03 | 2.005E-02 | SYK; MAPK1; PRKCA |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.275E-03 | 7.503E-03 | MAPK1; PRKCA; HIF1A |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 9.491E-03 | 2.288E-02 | GSK3B; MAPK1; PRKCA |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.125E-03 | 1.231E-02 | PTPN1; CSNK2A1; MAPK1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.385E-03 | 7.731E-03 | MAPK1; PRKCA; PTGS2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.866E-03 | 6.276E-03 | FABP4; PTGS2; TSHR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.506E-03 | 5.446E-03 | GSK3B; MAPK1; TP53 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 9.752E-03 | 2.292E-02 | MAPK1; PRKCA; HIF1A |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 9.491E-03 | 2.288E-02 | PRKCA; NFKB1; TLR2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.056E-02 | 2.420E-02 | GSK3B; MAPK1; NFKB1 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 9.752E-03 | 2.292E-02 | MAPK1; PRKCA; PTGS2 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.112E-02 | 2.488E-02 | MAPK1; NFKB1; TLR2 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.258E-02 | 2.751E-02 | ACHE; MAPK1; PRKCA |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.499E-03 | 7.962E-03 | GSK3B; MAPK1; TP53 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.056E-02 | 2.420E-02 | MAPK1; NFKB1; TLR2 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.690E-02 | 3.570E-02 | GSK3B; CDK6; TP53 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.482E-02 | 3.166E-02 | MMP2; PRKCA; MMP9 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.618E-02 | 4.778E-02 | POLB; GSK3B; TP53; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.992E-02 | 3.942E-02 | SYK; MAPK1; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.876E-02 | 3.791E-02 | GSK3B; MAOA; PRKCA |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 2.112E-02 | 4.094E-02 | SYK; MAPK1; PRKCA |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.279E-02 | 4.372E-02 | PTPN1; GSK3B; MAPK1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.497E-02 | 4.648E-02 | SYK; MAPK1; PRKCA |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 9.256E-04 | 3.783E-03 | ABCC1; CFTR; ABCG2 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.965E-04 | 1.394E-03 | AKR1B10; GAA; AKR1B1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.558E-02 | 4.714E-02 | MAPK1; NFKB1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 2.727E-02 | 4.929E-02 | AKR1B10; AKR1B1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.393E-02 | 4.499E-02 | NFKB1; TLR2 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 2.393E-02 | 4.499E-02 | GSK3B; TP53 |
| hsa05110 | Vibrio cholerae infection_Homo sapiens_hsa05110 | 2.078E-02 | 4.069E-02 | PRKCA; CFTR |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.927E-02 | 3.854E-02 | MAOA; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.854E-02 | 3.788E-02 | PKM; MAPK1 |
| hsa04961 | Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | 1.781E-02 | 3.680E-02 | PRKCA; ESR1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.710E-02 | 3.573E-02 | CYP3A4; XDH |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.249E-02 | 2.751E-02 | MAPK1; PRKCA |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 7.037E-03 | 1.917E-02 | MAPK1; TP53 |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.311E-02 | 2.832E-02 | PKM; GLO1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 8.524E-03 | 2.166E-02 | AKR1B10; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 9.049E-03 | 2.238E-02 | POLB; PARP1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.071E-02 | 2.425E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.460E-03 | 1.310E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.855E-04 | 1.090E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| NA: NA | Edema | NA | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; TLR2; CSNK2A1; SYK; CA1; FLT3; FLT3; CA9; MMP2; ACHE; PTGS2; CD38; GSK3B; HIF1A; MAPK1; MMP9; NFKB1; PARP1; TP53; ESR1; ESR1; APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; MMP9; TP53 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PTGS2; NFKB1; PPARD |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; FLT3; MMP2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; ACHE; PTGS2; PTGS2; PTGS2; PTGS2; ADRA2C; ADRA2A; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12; PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ABCC1; ALOX5; PTGS2; PTGS2; MMP1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; MMP12; PTGS2; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; SYK; ESR1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; MMP12; PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TLR2; FLT3; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TLR2; PKM; SYK; FLT3; CA9; MMP2; HIF1A; MAPK1; MMP9; TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; ALOX5; SYK; PTGS2; PTGS2; PTGS2; PTGS2; MMP1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; ACHE; CYP3A4 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; ESR1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; PPARD; PPARD |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; ADRA2C; APP |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; PARP1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PARP1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; PTPN1; GSK3B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; TP53; TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; CD38; TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |